Compare NOV Inc. Common Stock (NOV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NOV Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? NOV Inc. Common Stock trades at $18.75 (market cap $6.68B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: NOV Inc. Common Stock and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and NOV Inc. Common Stock pays a 1.92% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NOV Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NOV | SYRE | |
|---|---|---|
Market Cap | $6.68B | $7.35B |
Volume | 4,702,090 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $21.71 | $108.92 |
52-Week Low | $12.66 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.85B | $6.35B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.
The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NOV Inc. Common Stock
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
